MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference

CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced its participation at the virtual Needham 22nd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Monday, April 17, 2023 at 3:00 p.m. ET and management will be available for one-on-one meetings with institutional investors throughout the day.

About MBX Biosciences

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.

Media Inquiries:

Ian StoneEvoke Canale[email protected]619-849-5388

Investor Inquiries:

Irina KofflerLifeSci Advisors[email protected]917-734-7387

You May Also Be Interested In

• Computer Modelling Group Announces Annual General Meeting Voting Results
• Bitcoin Under Pressure, Ethereum Coils for Another Rally, 6 Best Crypto Presales That Could Move Next
• $9.9 Million Revenue for First Half of 2026, a 25% Increase Over Same Period in 2025 for Emerging AI and Robotics Developer Baird Medical Investment Holdings (Nasdaq: BDMD)